A recent metformin study casts doubts on longevity indications
A new retrospective study contradicts previous evidence of metformin’s potential effects on lifespan extension in a general population, but for real answers, randomized trials are needed.
In 2014, a retrospective study was published by Bannister et al . which laid the foundation for metformin – traditionally a first-line treatment for type II diabetes – to be regarded as a potential “anti-aging” drug for the general population. The authors of the U.K.-based study reported that diabetic patients on metformin monotherapy were found to have lower mortality than non-diabetic controls, despite the obvious baseline health bias favoring the control group. This remarkable finding suggests that this drug has benefits for lifespan beyond management of diabetes – benefits which could impr
Explore this link on the map →related reading
- Longevity FAQ - Laura Demingldeming.com
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- Milky Eggs >> Blog Archive >> Lifespan extension: separating fact from fictionmilkyeggs.com
- Nintil - The Longevity FAQnintil.com
- Checking your browser - reCAPTCHAncbi.nlm.nih.gov
- A primer on the current state of longevity researchowlposting.com
- Supplements | near.blognear.blog
- Aging Interventions from Older Publications that Deserve a New Look | Sarah Constantinsrconstantin.github.io
- Nintil - Beyond lifespan as a metric in aging research: why reprogramming is promisingnintil.com
- Genetic Cartography of Longevity in Humans and Mice: Current Landscape and Horizons - PMCncbi.nlm.nih.gov
- What we wish we knew entering the aging fieldlibrariesforthefuture.bio
- Recent Advances in Anti-Aging Medicine - PMCncbi.nlm.nih.gov